Sajan Abin, Griepp Daniel W, Hakmi Hazim, Sohail Amir H, Hunt Jackson, Wolf Michelle, Logman Zhanna
Department of Surgery, NYU Langone Hospital-Long Island, Mineola, NY.
Department of Radiology, Columbia University Irving Medical Center, New York, NY.
Ochsner J. 2021 Winter;21(4):419-424. doi: 10.31486/toj.20.0162.
Isosulfan blue dye, or Lymphazurin, is commonly used for sentinel lymph node biopsy during operative procedures for patients with breast cancer. Allergic reactions to Lymphazurin have been reported, ranging from mild dermatologic reactions to severe anaphylaxis. We report 2 patients who experienced allergic reaction to Lymphazurin while admitted to our service. We also conducted a literature search for similar cases using national databases. Included studies were limited to retrospective studies, case series, or case reports. Patient characteristics, reaction observed, and hospital course were extracted. Of the patients we report, both had grade 3 anaphylactic reactions requiring vasopressors to achieve hemodynamic stability. One patient required intensive care unit monitoring for 18 hours, and the other required overnight monitoring in the postanesthesia care unit. The literature revealed 29 studies reporting 108 patients with confirmed allergic reactions to Lymphazurin. Including the 2 patients in this series (total study n=110), most reactions were grade 3 (57/110, 51.8%), followed by grade 1 (40/110, 36.4%) and grade 2 (13/110, 11.8%). Among the patients who had individual hospital course reported (n=34), 23 patients required admission to the surgical intensive care unit. Of studies that reported cancellation or progression of surgery after the reaction, the surgical procedure was canceled for 12 of 26 patients (46.1%). Although severe anaphylactic reactions are more commonly reported, mild reactions occur more frequently but are likely underreported. Although no fatalities were reported in the cases included in this review, anaphylactic reactions to Lymphazurin pose significant risks. Operating room personnel should be familiar with potential reactions to recognize and treat them early.
异硫蓝染料(或专利蓝V)常用于乳腺癌患者手术过程中的前哨淋巴结活检。已有对专利蓝V过敏反应的报道,范围从轻度皮肤反应到严重过敏反应。我们报告了2例在我院住院期间对专利蓝V发生过敏反应的患者。我们还使用国家数据库对类似病例进行了文献检索。纳入的研究限于回顾性研究、病例系列或病例报告。提取了患者特征、观察到的反应及住院过程。在我们报告的患者中,两人均发生3级过敏反应,需要使用血管升压药来维持血流动力学稳定。一名患者需要在重症监护病房监测18小时,另一名患者需要在麻醉后护理病房过夜监测。文献显示有29项研究报告了108例确诊对专利蓝V过敏反应的患者。包括本系列中的2例患者(研究总数n = 110),大多数反应为3级(57/110,51.8%),其次是1级(40/110,36.4%)和2级(13/110,11.8%)。在报告了个体住院过程的患者中(n = 34),23例患者需要入住外科重症监护病房。在报告了反应后手术取消或进展情况的研究中,26例患者中有12例(46.1%)的手术被取消。虽然严重过敏反应报道更为常见,但轻度反应发生更频繁,可能未得到充分报告。尽管本综述纳入的病例中未报告死亡情况,但对专利蓝V的过敏反应仍构成重大风险。手术室人员应熟悉潜在反应以便早期识别和处理。